BioCentury | Apr 2, 2020
Product Development

Pitt delivers first peer-reviewed data for COVID-19 vaccine, to advance to clinic

...until it’s needed. The technology is in use in a Phase I trial to deliver doxorubicin...
BioCentury | Mar 27, 2020
Regulation

CHMP decisions set stage for approval of Novartis’ SMA gene therapy, Celgene’s Zeposia for MS, Sanofi’s comeback cancer drug

...NYSE:TAK) for first-line treatment of systemic anaplastic large cell lymphoma (sALCL) in combination with cyclophosphamide, doxorubicin...
BioCentury | Dec 12, 2019

Combined inhibition of CDK12 and CDK13 for TNBC

...of 15.5-24.9 nM. In three of the lines, the optimized compound plus generic chemotherapies cisplatin, doxorubicin...
BioCentury | Sep 12, 2019
Distillery Therapeutics

Tumor-targeted serum albumin-chemotherapy conjugates for improved delivery to breast and colorectal cancers

...values of 1.8 and 40.6 nM, respectively. Fusions conjugated to aldoxorubicin increased intratumoral accumulation of doxorubicin...
...to tumor rechallenge. CytRx Corp. and NantWorks LLC have aldoxorubicin, a 6-maleimidocaproyl hydrazone prodrug of doxorubicin...
BioCentury | Aug 22, 2019
Translation in Brief

Systems biology orders strategy to avoid cross-drug resistance in cancer

...biology modeling, the researchers identified sequential drug combinations that countered taxane-induced resistance to the anthracycline doxorubicin...
...maximum cancer killing. In particular, the model predicted optimal antitumor efficacy in taxane-resistant TNBC if doxorubicin...
...contrast, efficacy was lower if the metabolism inhibitor only partially coincided with or came after doxorubicin...
BioCentury | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

...Phase III testing for its mucositis candidate Validive clonidine lauriad and Phase II testing for doxorubicin...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...Taiwan Liposome Co. Ltd. (TPEx:4152; NASDAQ:TLC) On reexamination, CHMP again recommends against approval of Doxolipad doxorubicin...
BioCentury | Jun 7, 2019
Translation in Brief

Binding the extracellular matrix to target brain tissue

...to kidney, heart or liver tissues. The team linked VLRs to doxorubicin-loaded liposomes, which induced doxorubicin...
...team is seeking collaborators. Sandi Wong, Staff Writer University of Texas at Austin University of Wisconsin-Madison Neurology (unspecified) Brain cancer blood-brain barrier doxorubicin...
BioCentury | Jun 4, 2019
Distillery Therapeutics

Targeting brain extracellular matrix to improve doxorubicin efficacy in GBM

...DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest doxorubicin-loaded nanoparticles targeted to...
...to brain extracellular matrix (ECM) could help treat glioblastoma multiforme (GBM). The nanoparticles consist of doxorubicin-loaded...
...University of Wisconsin-Madison, Madison, Wis. email: eshusta@wisc.edu Sandi Wong University of Texas at Austin University of Wisconsin-Madison Brain cancer lamprey liposomal doxorubicin variable...
BioCentury | May 29, 2019
Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

...is marketed in the U.S. as Endari. Upon re-examination, CHMP recommended against approval of Doxolipad doxorubicin...
...cancer because the company failed to show that Doxolipad was bioequivalent to Caelyx pegylated liposomal doxorubicin...
...radicava) Syprine, trientine hydrochloride Emmaus Life Sciences Inc. Mitsubishi Tanabe Pharma Corp. Novartis AG Taiwan Liposome Co. Ltd. Cufence trientine hydrochloride Doxolipad doxorubicin LysaKare...
Items per page:
1 - 10 of 1364